Advancing Therapies for Patients

Find a clinical trial

page image


shadow image

Text Size

minus image

plus image

plus image


Print image

Email a Friend


Find a clinical trial

03 October 2016

Dr. Moschetta to present at ESMO Congress

Sarah Cannon Research Institute UK’s Drug Development Unit is proud to announce that Clinical Research Fellow Dr. Michele Moschetta’s research project “Dynamics of Neutrophil to Lymphocyte Ratio (NLR) Predict Effectiveness of PD1/PDL1 Inhibition” has been selected for presentation at the annual European Society for Medical Oncology (“ESMO”) Congress to be held in Copenhagen, Denmark from October 7-11.

In the study, Dr. Moschetta and colleagues found that changes in the ratio between the absolute number of these different types of white blood cells after only two doses of an immunotherapy agent can predict response to the treatment. This easy blood test, if validated in prospective clinical trials, could spare cancer patients to undergo expensive and possibly toxic treatments.

In addition, Dr. Moschetta  has been awarded a travel grant and complimentary registration to this prestigious conference.

Download the poster from the link below:

<< Back to News

Latest Videos

watch the latest videos.

Learn more


news from the industry.

Read more

hero1 image
Sarah Cannon Research UK NHS Ventures
University College London Hospitals